|
|
 Previous Article | Table of Contents | Next Article 
Comparison of Autologous Bone Marrow Transplantation and Intensive Chemotherapy as Postremission Therapy in Adult Acute Myeloid Leukemia
Jean-Luc Harousseau,
Jean-Yves Cahn,
Bernard Pignon,
Francis Witz,
Noël Milpied,
Martine Delain,
Bruno Lioure,
Thierry Lamy,
Bernard Desablens,
François Guilhot,
Denis Caillot,
Jean-François Abgrall,
Sylvie Francois,
Jean Briere,
Denis Guyotat,
Philippe Casassus,
Bruno Audhuy,
Zéra Tellier,
Patrick Hurteloup, and
Patrick Herve
From the Departments of Hematology of Centre Hospitalier Universitaire de Nantes, Nantes, France; Centre Hospitalier Universitaire de Besançon, Besançon, France; Centre Hospitalier Universitaire de Reims, Reims, France; Centre Hospitalier Universitaire de Nancy, Nancy, France; Centre Hospitalier Universitaire de Tours, Tours, France; Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France; Centre Hospitalier Universitaire de Rennes, Rennes, France; Centre Hospitalier Universitaire d'Amiens, Amiens, France; Centre Hospitalier Universitaire de Poitiers, Poitiers, France; Centre Hospitalier Universitaire de Dijon, Dijon, France; Centre Hospitalier Universitaire de Brest, Brest, France; Centre Hospitalier Universitaire d'Angers, Angers, France; Hôpital Beaujon Clichy, France; Centre Hospitalier Universitaire de Saint Etienne, Saint Etienne, France; Hôpital Avicenne, Bobigny, France; Hôpital de Colmar, Colmar, France; Pharmacia Upjohn Guyancourt, Guyancourt, France.
Three intensive consolidation strategies are currently proposed to younger adults with acute myeloid leukemia (AML) in first complete remission (CR): allogeneic or autologous bone marrow transplantation (BMT) and intensive consolidation chemotherapy (ICC). Patients aged 15 to 50 years with de novo AML received an induction treatment with 7 days of cytarabine and either idarubicin or rubidazone. After achievement of a CR, patients up to the age of 40 and having an HLA-identical sibling were assigned to undergo an allogeneic BMT. All the other patients received a first course of ICC with high-dose cytarabine and the same anthracycline as for induction. They were then randomly assigned to either receive a second course of ICC with amsacrine and etoposide or a combination of busulfan and cyclosphosphamide followed by an unpurged autologous BMT. Of 517 eligible patients, 367 had a CR, but only 219 (59.5%) actually received the planned intensive postremission treatment (73 allogeneic BMT, 75 autologous BMT, and 71 ICC). With a median follow-up of 62 months, the 4-year disease-free survival (DFS) of the 367 patients in CR was 39.5%. The 4-year overall survival (OS) of the 517 eligible patients was 40.5%. In multivariate analysis, DFS and OS were influenced only by the initial white blood cell count and by the French-American-British classification. The type of postremission therapy had no significant impact on the outcome. There was no difference in the 4-year DFS and OS between 88 patients for whom an allogeneic BMT was scheduled (respectively, 44% and 53%) and 134 patients of the same age category and without an HLA-identical sibling (respectively, 38% and 53%). Similarly, there was no difference in the outcome between autologous BMT and ICC. The 4-year DFS was 44% for the 86 patients randomly assigned to autologous BMT and 40% for the 78 patients assigned to ICC (P = .41). The 4-year OS was similar in the two groups (50% v 54.5%, P = .72). The median duration of hospitalization and thrombocytopenia were longer after autologous BMT (39 v 32 days, P = .006, and 109.5 v 18.5 days, P = .0001, respectively). After a first course of ICC, a second course of chemotherapy is less myelotoxic than an unpurged autologous BMT but yields comparable DFS and OS rates.
Blood, Vol. 90 No. 8 (July 15), 1997:
pp. 2978-2986
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
W. Blum
Post-remission therapy in acute myeloid leukemia: what should I do now?
Haematologica,
June 1, 2008;
93(6):
801 - 805.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Fouillard, M. Labopin, A. Gratwohl, E. Gluckman, F. Frassoni, D. W. Beelen, R. Willemze, E. Montserrat, D. Blaise, A. I. Atienza, et al.
Results of syngeneic hematopoietic stem cell transplantation for acute leukemia: risk factors for outcomes of adults transplanted in first complete remission
Haematologica,
June 1, 2008;
93(6):
834 - 841.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Maurillo, F. Buccisano, A. Spagnoli, G. Del Poeta, P. Panetta, B. Neri, M. I. Del Principe, C. Mazzone, M. I. Consalvo, A. Tamburini, et al.
Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow
Haematologica,
May 1, 2007;
92(5):
605 - 611.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Cornelissen, W. L. J. van Putten, L. F. Verdonck, M. Theobald, E. Jacky, S. M. G. Daenen, M. van Marwijk Kooy, P. Wijermans, H. Schouten, P. C. Huijgens, et al.
Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?
Blood,
May 1, 2007;
109(9):
3658 - 3666.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Gojo, A. Jiemjit, J. B. Trepel, A. Sparreboom, W. D. Figg, S. Rollins, M. L. Tidwell, J. Greer, E. J. Chung, M.-J. Lee, et al.
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias
Blood,
April 1, 2007;
109(7):
2781 - 2790.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Thomas, S. Suciu, B. Rio, G. Leone, G. Broccia, G. Fillet, U. Jehn, W. Feremans, G. Meloni, M. Vignetti, et al.
Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61 70 years: results of the prospective EORTC GIMEMA AML 13 study
Haematologica,
March 1, 2007;
92(3):
389 - 396.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y-B Yu, J-P Gau, J-Y You, H-H Chern, W-K Chau, C-H Tzeng, C-H Ho, and H-C Hsu
Cost-effectiveness of postremission intensive therapy in patients with acute leukemia
Ann. Onc.,
March 1, 2007;
18(3):
529 - 534.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Buchner, W. E. Berdel, C. Schoch, T. Haferlach, H. L. Serve, J. Kienast, S. Schnittger, W. Kern, J. Tchinda, A. Reichle, et al.
Double Induction Containing Either Two Courses or One Course of High-Dose Cytarabine Plus Mitoxantrone and Postremission Therapy by Either Autologous Stem-Cell Transplantation or by Prolonged Maintenance for Acute Myeloid Leukemia
J. Clin. Oncol.,
June 1, 2006;
24(16):
2480 - 2489.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Pagel, F. R. Appelbaum, J. F. Eary, J. Rajendran, D. R. Fisher, T. Gooley, K. Ruffner, E. Nemecek, E. Sickle, L. Durack, et al.
131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission
Blood,
March 1, 2006;
107(5):
2184 - 2191.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Hegenbart, D. Niederwieser, B. M. Sandmaier, M. B. Maris, J. A. Shizuru, H. Greinix, C. Cordonnier, B. Rio, A. Gratwohl, T. Lange, et al.
Treatment for Acute Myelogenous Leukemia by Low-Dose, Total-Body, Irradiation-Based Conditioning and Hematopoietic Cell Transplantation From Related and Unrelated Donors
J. Clin. Oncol.,
January 20, 2006;
24(3):
444 - 453.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. E. Gale, R. Hills, P. D. Kottaridis, S. Srirangan, K. Wheatley, A. K. Burnett, and D. C. Linch
No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials
Blood,
November 15, 2005;
106(10):
3658 - 3665.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Stelljes, M. Bornhauser, M. Kroger, J. Beyer, M. C. Sauerland, A. Heinecke, B. Berning, C. Scheffold, G. Silling, T. Buchner, et al.
Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia
Blood,
November 1, 2005;
106(9):
3314 - 3321.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Jourdan, J.-M. Boiron, N. Dastugue, N. Vey, G. Marit, F. Rigal-Huguet, L. Molina, N. Fegueux, A. Pigneux, C. Recher, et al.
Early Allogeneic Stem-Cell Transplantation for Young Adults With Acute Myeloblastic Leukemia in First Complete Remission: An Intent-to-Treat Long-Term Analysis of the BGMT Experience
J. Clin. Oncol.,
October 20, 2005;
23(30):
7676 - 7684.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Tallman, D. G. Gilliland, and J. M. Rowe
Drug therapy for acute myeloid leukemia
Blood,
August 15, 2005;
106(4):
1154 - 1163.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S. Farag, A. S. Ruppert, K. Mrozek, R. J. Mayer, R. M. Stone, A. J. Carroll, B. L. Powell, J. O. Moore, M. J. Pettenati, P. R.K. Koduru, et al.
Outcome of Induction and Postremission Therapy in Younger Adults With Acute Myeloid Leukemia With Normal Karyotype: A Cancer and Leukemia Group B Study
J. Clin. Oncol.,
January 20, 2005;
23(3):
482 - 493.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. C. Nathan, L. Sung, M. Crump, and J. Beyene
Consolidation Therapy With Autologous Bone Marrow Transplantation in Adults With Acute Myeloid Leukemia: A Meta-analysis
J Natl Cancer Inst,
January 7, 2004;
96(1):
38 - 45.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Buchner, W. Hiddemann, W. E. Berdel, B. Wormann, C. Schoch, C. Fonatsch, H. Loffler, T. Haferlach, W.-D. Ludwig, G. Maschmeyer, et al.
6-Thioguanine, Cytarabine, and Daunorubicin (TAD) and High-Dose Cytarabine and Mitoxantrone (HAM) for Induction, TAD for Consolidation, and Either Prolonged Maintenance by Reduced Monthly TAD or TAD-HAM-TAD and One Course of Intensive Consolidation by Sequential HAM in Adult Patients at All Ages With De Novo Acute Myeloid Leukemia (AML): A Randomized Trial of the German AML Cooperative Group
J. Clin. Oncol.,
December 15, 2003;
21(24):
4496 - 4504.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. J. Kell, A. K. Burnett, R. Chopra, J. A. L. Yin, R. E. Clark, A. Rohatiner, D. Culligan, A. Hunter, A. G. Prentice, and D. W. Milligan
A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia
Blood,
December 15, 2003;
102(13):
4277 - 4283.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Solary, B. Drenou, L. Campos, P. de Cremoux, F. Mugneret, P. Moreau, B. Lioure, A. Falkenrodt, B. Witz, M. Bernard, et al.
Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia
Blood,
August 15, 2003;
102(4):
1202 - 1210.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Suciu, F. Mandelli, T. de Witte, R. Zittoun, E. Gallo, B. Labar, G. De Rosa, A. Belhabri, R. Giustolisi, R. Delarue, et al.
Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial
Blood,
August 15, 2003;
102(4):
1232 - 1240.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Delaunay, N. Vey, T. Leblanc, P. Fenaux, F. Rigal-Huguet, F. Witz, T. Lamy, A. Auvrignon, D. Blaise, A. Pigneux, et al.
Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup
Blood,
July 15, 2003;
102(2):
462 - 469.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Lowenberg, J. D. Griffin, and M. S. Tallman
Acute Myeloid Leukemia and Acute Promyelocytic Leukemia
Hematology,
January 1, 2003;
2003(1):
82 - 101.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Stone
The Difficult Problem of Acute Myeloid Leukemia in the Older Adult
CA Cancer J Clin,
November 1, 2002;
52(6):
363 - 371.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Fouillard, M. Labopin, N.-C. Gorin, E. Polge, H. G. Prentice, G. Meloni, J. Reiffers, A. Pigneux, R. Willemze, A. Schattenberg, et al.
Hematopoietic stem cell transplantation for de novo erythroleukemia: a study of the European Group for Blood and Marrow Transplantation (EBMT)
Blood,
October 16, 2002;
100(9):
3135 - 3140.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Nguyen, T. Leblanc, P. Fenaux, F. Witz, D. Blaise, A. Pigneux, X. Thomas, F. Rigal-Huguet, B. Lioure, A. Auvrignon, et al.
A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup
Blood,
May 15, 2002;
99(10):
3517 - 3523.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. J. Giles, A. Keating, A. H. Goldstone, I. Avivi, C. L. Willman, and H. M. Kantarjian
Acute Myeloid Leukemia
Hematology,
January 1, 2002;
2002(1):
73 - 110.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
A. H. Goldstone, A. K. Burnett, K. Wheatley, A. G. Smith, R. M. Hutchinson, and R. E. Clark
Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial
Blood,
September 1, 2001;
98(5):
1302 - 1311.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Cutler and J. H. Antin
Peripheral Blood Stem Cells for Allogeneic Transplantation: A Review
Stem Cells,
February 1, 2001;
19(2):
108 - 117.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
F. R. Appelbaum, J. M. Rowe, J. Radich, and J. E. Dick
Acute Myeloid Leukemia
Hematology,
January 1, 2001;
2001(1):
62 - 86.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. L. Slovak, K. J. Kopecky, P. A. Cassileth, D. H. Harrington, K. S. Theil, A. Mohamed, E. Paietta, C. L. Willman, D. R. Head, J. M. Rowe, et al.
Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study
Blood,
December 15, 2000;
96(13):
4075 - 4083.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Venditti, F. Buccisano, G. Del Poeta, L. Maurillo, A. Tamburini, C. Cox, A. Battaglia, G. Catalano, B. Del Moro, L. Cudillo, et al.
Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia
Blood,
December 1, 2000;
96(12):
3948 - 3952.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Bruserud, G. Tjønnfjord, B. T. Gjertsen, B. Foss, and P. Ernst
New Strategies in the Treatment of Acute Myelogenous Leukemia: Mobilization and Transplantation of Autologous Peripheral Blood Stem Cells in Adult Patients
Stem Cells,
September 1, 2000;
18(5):
343 - 351.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
M. S. Tallman, P. A. Rowlings, G. Milone, M.-J. Zhang, W. S. Perez, D. Weisdorf, A. Keating, R. P. Gale, R. B. Geller, M. J. Laughlin, et al.
Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission
Blood,
August 15, 2000;
96(4):
1254 - 1258.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. D. Baynes, C. Hamm, R. Dansey, J. Klein, L. Cassells, C. Karanes, E. Abella, and W. P. Peters
Bone Marrow and Peripheral Blood Hematopoietic Stem Cell Transplantation: Focus on Autografting
Clin. Chem.,
August 1, 2000;
46(8):
1239 - 1251.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. Harousseau, B. Witz, B. Lioure, M. Hunault-Berger, B. Desablens, M. Delain, F. Guilhot, P. Y. Le Prise, J. F. Abgrall, E. Deconinck, et al.
Granulocyte Colony-Stimulating Factor After Intensive Consolidation Chemotherapy in Acute Myeloid Leukemia: Results of a Randomized Trial of the Groupe Ouest-Est Leucemies Aigues Myeloblastiques
J. Clin. Oncol.,
February 14, 2000;
18(4):
780 - 780.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Byrd, R. K. Dodge, A. Carroll, M. R. Baer, C. Edwards, J. Stamberg, M. Qumsiyeh, J. O. Moore, R. J. Mayer, F. Davey, et al.
Patients With t(8;21)(q22;q22) and Acute Myeloid Leukemia Have Superior Failure-Free and Overall Survival When Repetitive Cycles of High-Dose Cytarabine Are Administered
J. Clin. Oncol.,
December 1, 1999;
17(12):
3767 - 3775.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Lowenberg, J. R. Downing, and A. Burnett
Acute Myeloid Leukemia
N. Engl. J. Med.,
September 30, 1999;
341(14):
1051 - 1062.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. K. Parsons, S. Gelber, B. F. Cole, Y. Ravindranath, A. Ogden, A. M. Yeager, M. Chang, J. Shuster, H. J. Weinstein, and R. D. Gelber
Quality-Adjusted Survival After Treatment for Acute Myeloid Leukemia in Childhood: A Q-TWiST Analysis of the Pediatric Oncology Group Study 8821
J. Clin. Oncol.,
July 1, 1999;
17(7):
2144 - 2144.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Kanda, A. Miwa, A. Togawa, J. Perez-Calvo, A. Brugarolas, R. Suzuki, M. Seto, Y. Morishima, N.-C. Gorin, M. Labopin, et al.
Treatment of Acute Myeloid Leukemia
N. Engl. J. Med.,
May 6, 1999;
340(18):
1436 - 1439.
[Full Text]
|
|
|
|
